<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer</journal-id><journal-id journal-id-type="publisher-id">jca</journal-id><journal-title-group><journal-title>Journal of Cancer</journal-title></journal-title-group><issn pub-type="epub">1837-9664</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name><publisher-loc>Sydney</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786041</article-id><article-id pub-id-type="doi">10.7150/jca.104569</article-id><article-id pub-id-type="publisher-id">jcav16p1189</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>A Novel Nomogram for the Prediction and Evaluation of Prognosis in Patients with Early-onset Kidney Cancer: a Population-based Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Dingyang</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FNA_star" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qiwei</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FNA_star" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Ke</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_star" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jinshuai</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Huiyu</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Jie</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Shuang</surname><given-names>Weibing</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.</aff><aff id="A2"><label>2</label>First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi Province, China.</aff><aff id="A3"><label>3</label>Department of Pathology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.</aff><author-notes><corresp id="FNA_envelop">&#x02709; Corresponding author: Weibing Shuang (Email: <email>shuangweibing@126.com</email>).</corresp><fn fn-type="equal" id="FNA_star"><p>* These authors contributed equally to this work.</p></fn><fn fn-type="COI-statement"><p>Competing Interests: The authors have declared that no competing interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>1</month><year>2025</year></pub-date><volume>16</volume><issue>4</issue><fpage>1189</fpage><lpage>1201</lpage><history><date date-type="received"><day>2</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>). See <ext-link ext-link-type="uri" xlink:href="https://ivyspring.com/terms">https://ivyspring.com/terms</ext-link> for full terms and conditions.</license-p></license></permissions><abstract><p><bold>Background:</bold> Early-onset kidney cancer (EOKC) is often associated with genetic factors and a high risk of metastasis. However, there is a lack of accurate prediction models for the prognosis of EOKC. The aim of this study is to establish an effective nomogram for predicting and evaluating the prognosis of patients with EOKC.</p><p><bold>Methods:</bold> The patients with EOKC were selected from the latest SEER database during 2004-2015. Patients between 2004 and 2014 were randomly divided into a training cohort and a validation cohort at a ratio of 7:3, and patients in 2015 were used for temporal external validation. Additionally, we included patients from First Hospital of Shanxi Medical University between 2013 and 2021 for spatial external validation. The performance of the nomogram was assessed using the concordance index (C-index), receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Patients were stratified based on the nomogram, and Kaplan-Meier (KM) curves were plotted to compare the survival probability of patients.</p><p><bold>Results:</bold> In the temporal and spatial external validation cohort, the C-index of the nomogram for OS was 0.872 and 0.875, respectively, and the C-index of the nomogram for CSS were 0.872 and 0.851, respectively. In the temporal external validation cohort, the 1-year, 3-year and 5-year AUC of the nomogram for OS were 0.906, 0.899 and 0.876, respectively. In addition, the AUC showed that the nomogram had also high predictive ability for CSS. The calibration curves and DCA also indicated that the nomogram had a strong clinical utility. The KM curve revealed that patients in the low-risk group had a better prognosis than those in the high-risk group.</p><p><bold>Conclusion:</bold> Our study developed a novel high-performance nomogram for assessing the prognosis of patients with EOKC, and it has great potential for clinicians to assess patient prognosis and formulate effective intervention and follow-up strategies.</p></abstract><kwd-group><kwd>Early-onset kidney cancer</kwd><kwd>Nomogram</kwd><kwd>Overall survival</kwd><kwd>prognosis</kwd><kwd>SEER</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Renal cell carcinoma (RCC) is one of the most prevalent malignancies in the world, representing around 3~5% of all cancers <xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>. With the development of advanced imaging techniques, RCC can be detected and diagnosed earlier and more accurately, and its incidence is increasing annually. In 2020, there were an estimated 431,288 new cases of RCC globally <xref rid="B3" ref-type="bibr">3</xref>. RCC is the most prevalent solid lesion of the kidney and accounts for approximately 85% of all kidney cancer cases <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>. There are different histologic subtypes of RCC with specific histopathological and genetic characteristics <xref rid="B6" ref-type="bibr">6</xref>. The most prevalent subtype among them is clear cell renal cell carcinoma. There is a 1.5-2.0:1 predominance in men over women <xref rid="B7" ref-type="bibr">7</xref>. An epidemiological survey in the United States found that the incidence of RCC in young people (25-49 years old) increased significantly from 1995 to 2014, with an average annual growth rate of 2.95-6.23%, surpassing that observed in the middle-aged and elderly <xref rid="B8" ref-type="bibr">8</xref>. In 2014, Shuch et al. first defined early-onset kidney cancer (EOKC) as RCC diagnosed before the age of 47 (46 years or younger) <xref rid="B9" ref-type="bibr">9</xref>, which may be associated with genetic factors and a higher risk of metastasis <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>. Truong et al.'s research reported that approximately 18% of patients with EOKC harbored a germline P/LP variant, half of which are associated with hereditary RCC syndromes, and patients with EOKC should undergo comprehensive assessment of personal and family history to guide appropriate genetic testing <xref rid="B12" ref-type="bibr">12</xref>.</p><p>Accurate prediction of the prognosis of RCC is of crucial significance for clinical diagnosis and treatment. The traditional TNM staging system is the primary tool for most clinicians to evaluate the prognosis and develop diagnostic and treatment strategies for patients. However, this staging system does not include clinicopathological factors potentially influencing the prognosis of RCC, such as age, sex, basic diseases, surgical methods, histologic subtypes, grades, etc <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>. To overcome this limitation, Wang et al. established a nomogram to assess the prognosis of elderly patients with early RCC based on the Surveillance Epidemiology and End Results (SEER) database and validated its performance externally <xref rid="B15" ref-type="bibr">15</xref>. Huang et al. established and verified a nomogram for predicting cancer-specific survival in patients with metastatic clear cell RCC <xref rid="B16" ref-type="bibr">16</xref>. Leibovich et al. developed specific prognostic models for oncologic outcomes in clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), and chromophobe renal cell carcinoma (chRCC), providing vital prognostic predictive information <xref rid="B17" ref-type="bibr">17</xref>. These studies demonstrate the importance of clinicopathological factors as prognostic factors in predicting the prognosis and formulating treatment and follow-up strategies.</p><p>Nevertheless, there are few studies on the prognostic nomogram for EOKC, with only one reported study <xref rid="B18" ref-type="bibr">18</xref>. Therefore, it is necessary to further identify the independent prognostic factors of EOKC and establish a more effective prediction model for its clinical prognosis, providing guidance for clinical diagnosis and treatment decisions. Based on the SEER database, this study divided the data from 2004 to 2014 into a training cohort and a validation cohort, and the data from 2015 was used for external validation. Additionally, we included patients from First Hospital of Shanxi Medical University for spatial external validation. The training cohort was used for Cox regression analysis to construct a prognostic nomogram, then the prediction efficiency of the model was evaluated by the receiver operating characteristic (ROC) and other methods. The novel nomogram is expected to optimize individualized treatment decisions for patients with EOKC.</p></sec><sec sec-type="methods"><title>Patients and Methods</title><sec><title>Data source and data extraction</title><p>Data on young patients (aged &#x02264; 46 years) diagnosed with RCC from 2004 to 2015 were retrieved from the Incidence-SEER Research Data, 17 Registries, Nov 2022 Sub (2000-2020) using SEER*Stat 8.4.2. The demographic information, tumor characteristics and survival status of patients are publicly available through the SEER database. A total of 14,027 patients were included in the SEER database. Additionally, we included 176 patients from First Hospital of Shanxi Medical University between 2013 and 2021 for spatial external validation. Inclusion criteria: (1) Aged &#x02264; 46 years; (2) Malignant pathological diagnosis; (3) Pathological diagnosis is RCC: including RCC (8010, 8312), clear cell RCC (8310), papillary RCC (8050, 8260), chromophobe RCC (8270,8317), collecting duct carcinoma (8319), cyst-associated RCC (8316), sarcomatoid RCC (8318), medullary RCC (8510), and mixed RCC (8255, 8323); (4) unilateral tumors. Exclusion criteria: (1) T stage=T0, Tx, N stage=Nx, and M stage=Mx; (2) Unclear or unknown surgery type; (3) Unclear or unknown tumor size; (4) Unknown survival time. The flowchart for selecting patients is shown in Fig. <xref rid="F1" ref-type="fig">1</xref>. The study was approved by the ethics committee of First Hospital of Shanxi Medical University (2018K006). Informed consent was waived due to the retrospective nature of the study.</p></sec><sec><title>Variable selection</title><p>Demographic and clinical data were collected, including age at diagnosis, sex, race, marital status, histological type, grade, TNM stage, AJCC stage, tumor size, radiotherapy, chemotherapy, type of surgery, survival status, and survival time. Race was categorized into black, white, and other. Marital status at diagnosis was divided into married and other (single, widowed, divorced, or separated). The pathological grade was divided into well differentiated (Grade I), moderately differentiated (Grade II), poorly differentiated (Grade III), and undifferentiated (Grade IV). The surgical methods were divided into four groups: non-surgical group, local tumor excision (photodynamic therapy, cryosurgery, thermal ablation, laser excision, et al), partial nephrectomy (PN), and radical nephrectomy (RN).</p></sec><sec><title>Statistical analysis</title><p>We randomly divided 12,529 patients between 2004 and 2014 into a training cohort (n = 8770) and a validation cohort (n = 3759) at a ratio of 7:3. Patients from 2015 (n = 1498) were used for temporal external validation. Independent sample t-test and chi-square test were used to compare the clinicopathological variables between the training and validation cohorts. The Cox proportional hazards model was used for univariable and multivariable analysis to identify independent prognostic factors for EOKC. The hazard ratio (HR) and 95% confidence interval (CI) were calculated. Two new nomogram models were established using selected independent prognostic factors to estimate overall survival (OS) and cancer-specific survival (CSS) rates of patients with EOKC at 1 year, 3 years and 5 years.</p><p>The area under the ROC curve (AUC) and the Concordance Index (C-index) were calculated to evaluate the discriminative and predictive accuracy of the nomogram. The calibration curves (1000 bootstrap resamples) were constructed to validate the predictive efficiency of the nomogram. The clinical diagnostic significance of the nomogram was evaluated using Decision curve analysis (DCA), which is a new algorithm to assess the clinical utility by estimating the net benefit under each risk threshold <xref rid="B19" ref-type="bibr">19</xref>. Patients were divided into low-risk and high-risk groups according to the nomogram. Kaplan-Meier curve and log-rank test were used to compare the survival rates of patients between the two groups.</p><p>All statistical analyses were conducted using R version 4.3.1. The packages, including the &#x0201c;rms&#x0201d;, &#x0201c;survival&#x0201d;, &#x0201c;survminer&#x0201d;, &#x0201c;survivalROC&#x0201d;, and &#x0201c;dcurves&#x0201d; were used to construct and validate the nomogram, formulate the ROC and calibration curves, establish DCA, draw KM curves, and perform log-rank tests. When the P value was less than 0.05, the difference was considered statistically significant (two-sided).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Basic characteristics of patients</title><p>According to the inclusion and exclusion criteria, we included 14,027 patients with EOKC from the SEER database between 2004 and 2015. Patients from 2004 to 2014 (n=12,529) were used for the establishment and internal validation of predictive models. The mean age of the patients was 39.5&#x000b1;6.11 years, and there were 7,728 (61.7%) male and 4,801 (38.3%) female patients. The majority of patients were white (9,960, 79.5%), followed by black (1569, 12.5%) and other (1000, 8.0%). Among these patients, 7,114 (56.8%) were married and 5,415 (43.2%) were unmarried. The histologic subtypes of RCC included clear cell (7241, 57.8%), RCC (2422, 19.3%), papillary (1167, 9.3%), chromophobe (1007, 8.0%), and other (692, 5.5%). According to the grading system, there were 7356 (58.7%) patients with Grade I/II, 3076 (24.1%) with Grade III/IV, and 2097 (16.7%) with unknown grade. According to the AJCC staging system, there were 10,827 (86.4%) patients with T1/T2, 11,947 (95.4%) patients with N0, 11,722 (93.6%) patients with M0, and 9,050 (72.2%) patients with AJCC stage I. The mean tumor size was 5.05&#x000b1;4.03 cm. In addition, 278 (2.2%), 4777 (38.1%), and 6939 (55.4%) patients underwent local tumor excision, partial nephrectomy (PN), and radical nephrectomy (RN), respectively, with a small proportion of patients treated with radiotherapy (2.4%) and chemotherapy (5.2%). Patients from 2015 (n = 1498) were used for temporal external validation. The clinicopathological characteristics of EOKC patients in the training and two validation cohorts are shown in Table <xref rid="T1" ref-type="table">1</xref>. The P-values are the results of statistical analysis comparing the training set with the two validation queues, respectively. There were no significant differences in clinicopathologic characteristics between the training cohort and two validation cohorts.</p></sec><sec><title>Univariate and multivariate cox regression analysis</title><p>In the training cohort, univariate regression analyses identified 14 significant risk factors, including age, sex, race, marital status, histologic subtype, grade, TNM stage, AJCC stage, tumor size, radiotherapy, chemotherapy, and surgery type. Next, we selected these factors to establish a multivariate Cox model to determine independent prognostic factors. The results showed that age, sex, race, marital status, histologic subtype, grade, TNM stage, AJCC stage, tumor size, radiotherapy, and surgery type were independent prognostic factors for OS in patients (Table <xref rid="T2" ref-type="table">2</xref>). At the same time, univariate and multivariate analysis suggested that sex, race, histologic subtype, grade, TNM stage, AJCC stage, tumor size, radiotherapy, and surgery type were independent prognostic factors for CSS in patients (Table <xref rid="T3" ref-type="table">3</xref>).</p></sec><sec><title>Nomogram construction for the prediction of 1-, 3-, and 5-year OS and CSS</title><p>A nomogram model was constructed using the selected independent prognostic factors and the corresponding score for each parameter was listed (Fig. <xref rid="F2" ref-type="fig">2</xref>A). The nomogram could predict the 1-, 3- and 5-year OS. The line length of each variable in the nomogram represents its contribution to OS. The longer line length indicates the larger contribution. As shown in the nomogram, the surgery type was the strongest prognostic factor for OS, followed by AJCC stage and histologic subtype. Meanwhile, we constructed a nomogram to predict CSS in patients (Fig. <xref rid="F2" ref-type="fig">2</xref>B).</p></sec><sec><title>Validation of the nomogram</title><p>In the training and validation cohorts, the C-index of the nomogram for OS were 0.834 and 0.828, respectively, indicating that the nomogram had excellent distinguishability. In the temporal and spatial external validation cohort, the C-index was 0.872 and 0.875, respectively. While the C-index of the nomogram for CSS in the training, validation, temporal and spatial external validation cohorts were 0.923, 0.828, 0.872 and 0.851, respectively. In the training cohort, the 1-year, 3-year and 5-year AUC of the nomogram for OS were 0.933, 0.912 and 0.884, respectively (Fig. <xref rid="F3" ref-type="fig">3</xref>A). In the validation cohort, the 1-year, 3-year and 5-year AUC of the nomogram for OS were 0.922, 0.898 and 0.872, respectively (Fig. <xref rid="F3" ref-type="fig">3</xref>B). In the temporal external validation cohort, the 1-year, 3-year and 5-year AUC of the nomogram for OS were 0.906, 0.899 and 0.876, respectively (Fig. <xref rid="F3" ref-type="fig">3</xref>C). The results indicated that the nomogram had high predictive ability. In addition, the AUC showed that the nomogram had high predictive ability for CSS (Fig. <xref rid="F3" ref-type="fig">3</xref>D-F). The 1-year, 3-year and 5-year calibration curves were also conducted to assess the difference in survival probability between the nomogram's prediction and the actual observation, and the results showed that the predicted curves approximatively overlapped with the diagonal line in the training cohort (Fig. <xref rid="F4" ref-type="fig">4</xref>A-C) and the validation cohort (Fig. <xref rid="F4" ref-type="fig">4</xref>D-F), suggesting the high prediction accuracy of the nomogram for OS. The 1-year, 3-year and 5-year calibration curves for CSS also showed the high prediction accuracy of the nomogram (Fig. <xref rid="F5" ref-type="fig">5</xref>A-F).</p></sec><sec><title>Clinical application of the nomogram</title><p>DCA results showed that applying the nomogram to guide clinical practice could provide EOKC patients with more net benefits than the TNM stage system in the training and validation cohorts, especially the long-term benefits at 3 and 5 years (Fig. <xref rid="F6" ref-type="fig">6</xref>A-D). The DCA of the temporal and spatial external validation cohort also suggested the high clinical value of the nomogram (Fig. <xref rid="F7" ref-type="fig">7</xref>A-D). To further optimize the clinical application of the nomogram, we developed a risk stratification system based on the total scores of patients in the nomogram. Patients were divided into a low-risk group (total score &#x02264; 280.1) and a high-risk group (total score &#x0003e; 280.1). In the training and validation cohorts, patients showed shorter OS in the high-risk group than in the low-risk group (Fig. <xref rid="F8" ref-type="fig">8</xref>A, B). The CSS of patients showed similar results (Fig. <xref rid="F8" ref-type="fig">8</xref>C, D).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>With the development of medical imaging technology, an increasing number of young patients have been diagnosed with renal cancer. An epidemiological study shows that the incidence of RCC in young people is rapidly increasing, and the average annual growth rate is higher than that in the middle-aged and elderly <xref rid="B8" ref-type="bibr">8</xref>. In addition, there are some differences in pathology, genetics and prognosis between young and old RCC patients <xref rid="B9" ref-type="bibr">9</xref>. Accurate prediction of the prognosis of patients with EOKC can improve treatment strategies, survival outcomes and follow-up care.</p><p>At present, the research on the prognosis of EOKC is very limited, and only one study has been reported <xref rid="B18" ref-type="bibr">18</xref>, in which the authors constructed a nomogram of EOKC and internally validated its performance. In this study, we included more clinicopathological factors, such as marital status, tumor size, and surgical methods, and performed the temporal and spatial external validation. The results showed that the proposed nomogram exhibited high prediction performance in both internal and external validations.</p><p>The two novel nomograms were constructed using a large number of clinical samples extracted from the SEER database to predict the prognosis of patients with EOKC. In clinical research, doctors and researchers often use the TNM staging system to evaluate patients' prognosis and make clinical decisions. However, compared to the traditional TNM staging system, recent studies have shown that the nomogram constructed based on clinicopathological data has higher accuracy in predicting patient survival <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>. Therefore, urologists can use the nomogram to evaluate the prognosis of EOKC patients and develop effective and individualized treatment strategies, thereby reducing the risk of death.</p><p>Multivariate cox regression analysis showed that age, sex, race, marital status, tumor grade, TNM stage, AJCC stage, tumor size, radiotherapy and surgical methods had significant effects on OS. These factors except for age and marital status were also independent prognostic factors for CSS in patients with EOKC. Age has been proven to be a key factor in the prognosis of various cancers <xref rid="B22" ref-type="bibr">22</xref>-<xref rid="B24" ref-type="bibr">24</xref>. With increasing age, the patient's immune function and physical condition are declining, which may lead to tumor deterioration and an increased risk of death. This is also consistent with our previous research <xref rid="B25" ref-type="bibr">25</xref>. Epidemiological studies show that the incidence and degree of malignancy of RCC are higher in males than in females <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>, which may be related to sex hormones. In addition, Ning et al. also found that the androgen-androgen receptor axis causes the exhaustion of CD8+ T-cells in the tumor microenvironment of male RCC patients <xref rid="B27" ref-type="bibr">27</xref>, resulting in impaired anti-tumor function of these cells. All of these may lead to poor prognosis. Stafford et al. analyzed the relationship between demographic factors and death in patients with kidney cancer based on the California Cancer Registry and found that the survival rate of black patients is lower than that of whites and other races in the USA <xref rid="B28" ref-type="bibr">28</xref>. Alam et al. found a similar result based on the National Cancer Database in the US <xref rid="B29" ref-type="bibr">29</xref>. These results are also consistent with ours. In addition, this study showed that marital status was a significant predictor of OS in RCC patients. Married patients can receive more emotional comfort and financial support from their family partners, resulting in a better prognosis <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>. This is consistent with the previous research <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B32" ref-type="bibr">32</xref>.</p><p>Tumor grade is another important prognostic factor for patients with EOKC. Our results are consistent with previous reports <xref rid="B33" ref-type="bibr">33</xref>-<xref rid="B36" ref-type="bibr">36</xref>. In general, a high tumor grade indicates a low degree of differentiation but a high degree of malignancy, which may result in a poor prognosis. It has become a consensus that the TNM stage can affect the prognosis of patients with many kinds of tumors <xref rid="B37" ref-type="bibr">37</xref>. In this study, the nomogram showed that the AJCC stage made a greater contribution to the prognosis of patients compared with T stage, N stage and M stage. This is because the AJCC stage is a combination of T, N and M stages to assess the prognosis of patients with EOKC, indicating that this staging system had a more clinical value. Our results also showed that radiotherapy could be used to predict the prognosis of patients, possibly due to the fact that patients undergoing radiotherapy often have metastasis, which results in a poor prognosis. At the same time, radiotherapy has been considered a double-edged sword. Long-term radiotherapy can cause damage to the immune system and physiological function, which may lead to severe disability and mortality <xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>. In this study, we found that patients undergoing PN had the longest OS, followed by those who underwent local tumor resection, RN and non-surgery treatment. This aligns with previous research findings related to RCC <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B40" ref-type="bibr">40</xref>. Local RCC can usually be removed by surgery and have a good prognosis. Among them, patients treated with PN had a better prognosis than those treated with RN. Generally, patients undergoing RN typically present tumors situated in intricate locations or infiltrating adjacent organs. In such cases, patients are more likely to develop distant metastasis even after surgery <xref rid="B41" ref-type="bibr">41</xref>. The prognosis is usually poor for patients who have not undergone surgery, since they are often in advanced stages or have metastasis.</p><p>The nomogram constructed in this study included demographic and clinicopathological factors, which are easy to collect in clinical practice. Across the four cohorts, this nomogram exhibited higher C-index and AUC values, suggesting that it had high accuracy and discrimination. In the training and internal validation cohorts, the calibration curves also showed a promising prediction performance. However, despite high accuracy and discriminative ability, their clinical applicability remains uncertain. Therefore, we conducted DCA and confirmed that the clinical net benefit of the nomogram outweighed that of the TNM staging system, particularly long-term benefits at 3 and 5 years. In addition, we utilized the risk scores derived from the nomogram to stratify the patients into different risk groups, and the results showed that the prognosis of patients in the high-risk group was significantly lower than that in the low-risk group. The results suggest that clinicians can identify high-risk patients according to the risk scores and implement appropriate therapeutic strategies to improve the prognosis of patients. Full evaluation should be made for high-risk patients, appropriate targeted therapy and immunotherapy should be used, and follow-up intervals should be shortened.</p><p>This study has several limitations. First, as a retrospective study, it faces challenges related to selection bias. Therefore, it is needed to conduct a large-scale prospective clinical study to validate the accuracy of the nomogram in the future. Second, the temporal external validation cohort for this study includes data from 2015, which is relatively early. However, incorporating data between 2013 and 2021 from our hospital for spatial external validation still demonstrates robust predictive performance. Additionally, the SEER database lacks information on comorbidities, such as complications, hypertension, BMI, etc. Nevertheless, the nomogram took some crucial determinants, such as tumor stages and grades, into account, and it still had great potential to be used in clinical practices.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In this study, we constructed a novel nomogram for predicting the prognosis of patients with EOKC based on the large-scale clinical data derived from the SEER database. This nomogram exhibited higher prediction performance. Clinicians can utilize this tool to assess the prognostic risk of patients and formulate effective intervention and follow-up strategies. In the future, more prospective clinical studies are essential to validate this nomogram and improve its clinical applicability.</p></sec></body><back><ack><p>We would like to thank the SEER program for providing this database.</p><sec><title>Funding</title><p>The research was supported by Emerging Industry Leading Talent Project of Shanxi Province (No. 2020587).</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The SEER data is available at <ext-link xlink:href="https://seer.Cancer.gov/" ext-link-type="uri">https://seer.Cancer.gov/</ext-link>. The data from our hospital are available from the corresponding author upon rational request.</p></sec><sec><title>Ethics approval statement</title><p>The research has been approved by the ethics committee of First Hospital of Shanxi Medical University (2018K006).</p></sec></ack><glossary><title>Abbreviations</title><def-list><def-item><term id="GL1">RCC</term><def><p>renal cell carcinoma</p></def></def-item><def-item><term id="GL2">EOKC</term><def><p>early-onset kidney cancer</p></def></def-item><def-item><term id="GL3">SEER</term><def><p>Surveillance Epidemiology and End Results</p></def></def-item><def-item><term id="GL4">ccRCC</term><def><p>clear cell renal cell carcinoma</p></def></def-item><def-item><term id="GL5">pRCC</term><def><p>papillary renal cell carcinoma</p></def></def-item><def-item><term id="GL6">chRCC</term><def><p>chromophobe renal cell carcinoma</p></def></def-item><def-item><term id="GL7">ROC</term><def><p>receiver operating characteristic</p></def></def-item><def-item><term id="GL8">PN</term><def><p>partial nephrectomy</p></def></def-item><def-item><term id="GL9">RN</term><def><p>radical nephrectomy</p></def></def-item><def-item><term id="GL10">HR</term><def><p>hazard ratio</p></def></def-item><def-item><term id="GL11">CI</term><def><p>confidence interval</p></def></def-item><def-item><term id="GL12">OS</term><def><p>overall survival</p></def></def-item><def-item><term id="GL13">CSS</term><def><p>cancer-specific survival</p></def></def-item><def-item><term id="GL14">AUC</term><def><p>area under the ROC curve</p></def></def-item><def-item><term id="GL15">C-index</term><def><p>Concordance Index</p></def></def-item><def-item><term id="GL16">DCA</term><def><p>Decision curve analysis</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Giaquinto</surname><given-names>AN</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><article-title>Cancer statistics, 2024</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>12</fpage><lpage>49</lpage>
<pub-id pub-id-type="pmid">38230766</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><name><surname>Capitanio</surname><given-names>U</given-names></name><name><surname>Bensalah</surname><given-names>K</given-names></name><name><surname>Bex</surname><given-names>A</given-names></name><name><surname>Boorjian</surname><given-names>SA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Coleman</surname><given-names>J</given-names></name><etal/><article-title>Epidemiology of Renal Cell Carcinoma</article-title><source>Eur Urol</source><year>2019</year><volume>75</volume><fpage>74</fpage><lpage>84</lpage>
<pub-id pub-id-type="pmid">30243799</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><name><surname>Bukavina</surname><given-names>L</given-names></name><name><surname>Bensalah</surname><given-names>K</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Carlo</surname><given-names>M</given-names></name><name><surname>Challacombe</surname><given-names>B</given-names></name><name><surname>Karam</surname><given-names>JA</given-names></name><etal/><article-title>Epidemiology of Renal Cell Carcinoma: 2022 Update</article-title><source>Eur Urol</source><year>2022</year><volume>82</volume><fpage>529</fpage><lpage>42</lpage>
<pub-id pub-id-type="pmid">36100483</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><article-title>Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome</article-title><source>Signal Transduct Target Ther</source><year>2019</year><volume>4</volume><fpage>41</fpage>
<pub-id pub-id-type="pmid">31637019</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><article-title>Cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><fpage>7</fpage><lpage>30</lpage>
<pub-id pub-id-type="pmid">31912902</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Cubilla</surname><given-names>AL</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Ulbright</surname><given-names>TM</given-names></name><article-title>The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours</article-title><source>Eur Urol</source><year>2016</year><volume>70</volume><fpage>93</fpage><lpage>105</lpage>
<pub-id pub-id-type="pmid">26935559</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><name><surname>Tahbaz</surname><given-names>R</given-names></name><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Merseburger</surname><given-names>AS</given-names></name><article-title>Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition</article-title><source>Curr Opin Urol</source><year>2018</year><volume>28</volume><fpage>62</fpage><lpage>79</lpage>
<pub-id pub-id-type="pmid">29059103</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Rosenberg</surname><given-names>PS</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><article-title>Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry</article-title><source>Lancet Public Health</source><year>2019</year><volume>4</volume><fpage>e137</fpage><lpage>e47</lpage>
<pub-id pub-id-type="pmid">30733056</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><name><surname>Shuch</surname><given-names>B</given-names></name><name><surname>Vourganti</surname><given-names>S</given-names></name><name><surname>Ricketts</surname><given-names>CJ</given-names></name><name><surname>Middleton</surname><given-names>L</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><etal/><article-title>Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><fpage>431</fpage><lpage>7</lpage>
<pub-id pub-id-type="pmid">24378414</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><name><surname>Haas</surname><given-names>NB</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><article-title>Hereditary kidney cancer syndromes</article-title><source>Adv Chronic Kidney Dis</source><year>2014</year><volume>21</volume><fpage>81</fpage><lpage>90</lpage>
<pub-id pub-id-type="pmid">24359990</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><name><surname>Adeniran</surname><given-names>AJ</given-names></name><name><surname>Shuch</surname><given-names>B</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><article-title>Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features</article-title><source>Am J Surg Pathol</source><year>2015</year><volume>39</volume><fpage>e1</fpage><lpage>e18</lpage>
<pub-id pub-id-type="pmid">26559379</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><name><surname>Truong</surname><given-names>H</given-names></name><name><surname>Sheikh</surname><given-names>R</given-names></name><name><surname>Kotecha</surname><given-names>R</given-names></name><name><surname>Kemel</surname><given-names>Y</given-names></name><name><surname>Reisz</surname><given-names>PA</given-names></name><name><surname>Lenis</surname><given-names>AT</given-names></name><etal/><article-title>Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing</article-title><source>Eur Urol Oncol</source><year>2021</year><volume>4</volume><fpage>993</fpage><lpage>1000</lpage>
<pub-id pub-id-type="pmid">34654685</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><name><surname>Gettman</surname><given-names>MT</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Spotts</surname><given-names>B</given-names></name><name><surname>Bryant</surname><given-names>SC</given-names></name><name><surname>Zincke</surname><given-names>H</given-names></name><article-title>Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system</article-title><source>Cancer</source><year>2001</year><volume>91</volume><fpage>354</fpage><lpage>61</lpage>
<pub-id pub-id-type="pmid">11180082</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><name><surname>Leibovich</surname><given-names>BC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Crispen</surname><given-names>PL</given-names></name><name><surname>Boorjian</surname><given-names>SA</given-names></name><name><surname>Thompson</surname><given-names>RH</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><etal/><article-title>Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma</article-title><source>J Urol</source><year>2010</year><volume>183</volume><fpage>1309</fpage><lpage>15</lpage>
<pub-id pub-id-type="pmid">20171681</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Yue</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><etal/><article-title>A web-based prediction model for overall survival of elderly patients with early renal cell carcinoma: a population-based study</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><fpage>90</fpage>
<pub-id pub-id-type="pmid">35164796</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Ba</surname><given-names>L</given-names></name><etal/><article-title>Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>949058</fpage>
<pub-id pub-id-type="pmid">36237316</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><name><surname>Leibovich</surname><given-names>BC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Zaid</surname><given-names>HB</given-names></name><name><surname>Boorjian</surname><given-names>SA</given-names></name><name><surname>Frank</surname><given-names>I</given-names></name><etal/><article-title>Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery</article-title><source>Eur Urol</source><year>2018</year><volume>73</volume><fpage>772</fpage><lpage>780</lpage>
<pub-id pub-id-type="pmid">29398265</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><etal/><article-title>Development and Validation of Prognostic Nomogram for Young Patients with Kidney Cancer</article-title><source>Int J Gen Med</source><year>2021</year><volume>14</volume><fpage>5091</fpage><lpage>103</lpage>
<pub-id pub-id-type="pmid">34511991</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><name><surname>Vickers</surname><given-names>AJ</given-names></name><name><surname>Cronin</surname><given-names>AM</given-names></name><name><surname>Elkin</surname><given-names>EB</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><article-title>Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers</article-title><source>BMC Med Inform Decis Mak</source><year>2008</year><volume>8</volume><fpage>53</fpage>
<pub-id pub-id-type="pmid">19036144</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><name><surname>Brateanu</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Kattan</surname><given-names>MW</given-names></name><name><surname>Olender</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>C</given-names></name><article-title>A nomogram to predict the probability of passing the American Board of Internal Medicine examination</article-title><source>Med Educ Online</source><year>2012</year><volume>17</volume><fpage>18810</fpage>
<pub-id pub-id-type="pmid">23078794</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><etal/><article-title>Clinical Nomogram for Predicting Survival of Esophageal Cancer Patients after Esophagectomy</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>26684</fpage>
<pub-id pub-id-type="pmid">27215834</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><name><surname>Eguchi</surname><given-names>T</given-names></name><name><surname>Bains</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Tan</surname><given-names>KS</given-names></name><name><surname>Hristov</surname><given-names>B</given-names></name><name><surname>Buitrago</surname><given-names>DH</given-names></name><etal/><article-title>Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>281</fpage><lpage>90</lpage>
<pub-id pub-id-type="pmid">28095268</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><name><surname>Yamano</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Babaya</surname><given-names>A</given-names></name><name><surname>Hamanaka</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><etal/><article-title>Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study</article-title><source>Eur J Cancer</source><year>2017</year><volume>81</volume><fpage>90</fpage><lpage>101</lpage>
<pub-id pub-id-type="pmid">28622612</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><name><surname>Pettersson</surname><given-names>A</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Garmo</surname><given-names>H</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><name><surname>Stattin</surname><given-names>P</given-names></name><article-title>Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><fpage>377</fpage><lpage>85</lpage>
<pub-id pub-id-type="pmid">29161337</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><name><surname>Cui</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>D</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Rong</surname><given-names>Y</given-names></name><etal/><article-title>Preoperative serum low-density lipoprotein cholesterol is an independent prognostic factor in patients with renal cell carcinoma after nephrectomy</article-title><source>Lipids Health Dis</source><year>2023</year><volume>22</volume><fpage>26</fpage>
<pub-id pub-id-type="pmid">36814277</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Wagle</surname><given-names>NS</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><article-title>Cancer statistics, 2023</article-title><source>CA Cancer J Clin</source><year>2023</year><volume>73</volume><fpage>17</fpage><lpage>48</lpage>
<pub-id pub-id-type="pmid">36633525</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><name><surname>Ning</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><etal/><article-title>Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8(+) T-cells highly infiltrated in males</article-title><source>Biol Sex Differ</source><year>2023</year><volume>14</volume><fpage>58</fpage>
<pub-id pub-id-type="pmid">37715192</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><name><surname>Stafford</surname><given-names>HS</given-names></name><name><surname>Saltzstein</surname><given-names>SL</given-names></name><name><surname>Shimasaki</surname><given-names>S</given-names></name><name><surname>Sanders</surname><given-names>C</given-names></name><name><surname>Downs</surname><given-names>TM</given-names></name><name><surname>Sadler</surname><given-names>GR</given-names></name><article-title>Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival</article-title><source>J Urol</source><year>2008</year><volume>179</volume><fpage>1704</fpage><lpage>8</lpage>
<pub-id pub-id-type="pmid">18343443</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><name><surname>Alam</surname><given-names>R</given-names></name><name><surname>Rezaee</surname><given-names>ME</given-names></name><name><surname>Pallauf</surname><given-names>M</given-names></name><name><surname>Elias</surname><given-names>R</given-names></name><name><surname>Yerrapragada</surname><given-names>A</given-names></name><name><surname>Enikeev</surname><given-names>D</given-names></name><etal/><article-title>Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma</article-title><source>Urol Oncol</source><year>2023</year><volume>41</volume><fpage>460</fpage><comment>e1- e9</comment>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/><article-title>Marital status is an independent prognostic factor for pancreatic neuroendocrine tumors patients: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2017</year><volume>41</volume><fpage>476</fpage><lpage>86</lpage>
<pub-id pub-id-type="pmid">28416359</pub-id>
</element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><name><surname>Aizer</surname><given-names>AA</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>McCarthy</surname><given-names>EP</given-names></name><name><surname>Mendu</surname><given-names>ML</given-names></name><name><surname>Koo</surname><given-names>S</given-names></name><name><surname>Wilhite</surname><given-names>TJ</given-names></name><etal/><article-title>Marital status and survival in patients with cancer</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3869</fpage><lpage>76</lpage>
<pub-id pub-id-type="pmid">24062405</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/><article-title>A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study</article-title><source>Front Public Health</source><year>2022</year><volume>10</volume><fpage>989566</fpage>
<pub-id pub-id-type="pmid">36276376</pub-id>
</element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><name><surname>Leibovich</surname><given-names>BC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Crispen</surname><given-names>PL</given-names></name><name><surname>Boorjian</surname><given-names>SA</given-names></name><name><surname>Thompson</surname><given-names>RH</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><etal/><article-title>Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma</article-title><source>J Urology</source><year>2010</year><volume>183</volume><fpage>1309</fpage><lpage>15</lpage>
</element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Bian</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/><article-title>Development and Validation of a Nomogram Predicting the Prognosis of Renal Cell Carcinoma After Nephrectomy</article-title><source>Cancer Manag Res</source><year>2020</year><volume>12</volume><fpage>4461</fpage><lpage>73</lpage>
<pub-id pub-id-type="pmid">32606940</pub-id>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Shuch</surname><given-names>B</given-names></name><name><surname>Kluger</surname><given-names>H</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Adeniran</surname><given-names>AJ</given-names></name><article-title>High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis</article-title><source>Am J Surg Pathol</source><year>2020</year><volume>44</volume><fpage>582</fpage><lpage>93</lpage>
<pub-id pub-id-type="pmid">32101890</pub-id>
</element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/><article-title>Pre-existing type 2 diabetes is an adverse prognostic factor in patients with renal cell carcinoma</article-title><source>J Diabetes</source><year>2019</year><volume>11</volume><fpage>993</fpage><lpage>1001</lpage>
<pub-id pub-id-type="pmid">31141620</pub-id>
</element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><name><surname>Nese</surname><given-names>N</given-names></name><name><surname>Paner</surname><given-names>GP</given-names></name><name><surname>Mallin</surname><given-names>K</given-names></name><name><surname>Ritchey</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name><article-title>Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base</article-title><source>Ann Diagn Pathol</source><year>2009</year><volume>13</volume><fpage>1</fpage><lpage>8</lpage>
<pub-id pub-id-type="pmid">19118775</pub-id>
</element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><name><surname>De Meerleer</surname><given-names>G</given-names></name><name><surname>Khoo</surname><given-names>V</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Joniau</surname><given-names>S</given-names></name><name><surname>Bossi</surname><given-names>A</given-names></name><name><surname>Ost</surname><given-names>P</given-names></name><etal/><article-title>Radiotherapy for renal-cell carcinoma</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>e170</fpage><lpage>7</lpage>
<pub-id pub-id-type="pmid">24694640</pub-id>
</element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><name><surname>Siva</surname><given-names>S</given-names></name><name><surname>Kothari</surname><given-names>G</given-names></name><name><surname>Muacevic</surname><given-names>A</given-names></name><name><surname>Louie</surname><given-names>AV</given-names></name><name><surname>Slotman</surname><given-names>BJ</given-names></name><name><surname>Teh</surname><given-names>BS</given-names></name><etal/><article-title>Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach</article-title><source>Nat Rev Urol</source><year>2017</year><volume>14</volume><fpage>549</fpage><lpage>63</lpage>
<pub-id pub-id-type="pmid">28631740</pub-id>
</element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><article-title>Prognosis of clear cell renal cell carcinoma patients stratified by age: A research relied on SEER database</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>975779</fpage>
<pub-id pub-id-type="pmid">36313677</pub-id>
</element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><name><surname>Dabestani</surname><given-names>S</given-names></name><name><surname>Thorstenson</surname><given-names>A</given-names></name><name><surname>Lindblad</surname><given-names>P</given-names></name><name><surname>Harmenberg</surname><given-names>U</given-names></name><name><surname>Ljungberg</surname><given-names>B</given-names></name><name><surname>Lundstam</surname><given-names>S</given-names></name><article-title>Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study</article-title><source>World J Urol</source><year>2016</year><volume>34</volume><fpage>1081</fpage><lpage>6</lpage>
<pub-id pub-id-type="pmid">26847337</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1</label><caption><p>The flowchart of the EOKC patients with training and validation cohorts.</p></caption><graphic xlink:href="jcav16p1189g001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Nomograms for the prognosis in patients with EOKC (Age, years; Tumor size, mm). (A) Nomogram for prediction of 1-, 3-, and 5-year OS. (B) Nomogram for prediction of 1-, 3-, and 5-year CSS.</p></caption><graphic xlink:href="jcav16p1189g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>The ROC for 1-, 3- and 5-year prognosis. (A) The ROC of nomogram for OS in training cohort. (B) The ROC of nomogram for OS in validation cohort. (C) The ROC of nomogram for OS in external validation cohort. (D) The ROC of nomogram for CSS in the training cohort. (E) The ROC of nomogram for CSS validation cohort. (F) The ROC of nomogram for CSS external validation cohort.</p></caption><graphic xlink:href="jcav16p1189g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Calibration curves of the nomogram. (A) 1-year OS in the training cohort. (B) 3-year OS in the training cohort. (C) 5-year OS in the training cohort. (D) 1-year OS in the validation cohort. (E) 3-year OS in the validation cohort. (F) 5-year OS in the validation cohort.</p></caption><graphic xlink:href="jcav16p1189g004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>Calibration curves of the nomogram. (A) 1-year CSS in the training cohort. (B) 3-year CSS in the training cohort. (C) 5-year CSS in the training cohort. (D) 1-year CSS in the validation cohort. (E) 3-year CSS in the validation cohort. (F) 5-year CSS in the validation cohort.</p></caption><graphic xlink:href="jcav16p1189g005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>Decision curves of the nomogram predicting OS and CSS in the training cohort. (A) DCA curves of the nomogram predicting OS in the training cohort. (B) DCA curves of the nomogram predicting OS in validation cohort. (C) DCA curves of the nomogram predicting CSS in the training cohort. (D) DCA curves of the nomogram predicting CSS in validation cohort.</p></caption><graphic xlink:href="jcav16p1189g006" position="float"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>Decision curves of the nomogram predicting OS and CSS in both temporal and spatial external validation cohort. (A) DCA curves of the nomogram predicting OS in the temporal external validation cohort. (B) DCA curves of the nomogram predicting OS in the spatial external validation cohort. (C) DCA curves of the nomogram predicting CSS in the temporal external validation cohort. (D) DCA curves of the nomogram predicting CSS in the spatial external validation cohort.</p></caption><graphic xlink:href="jcav16p1189g007" position="float"/></fig><fig position="float" id="F8"><label>Figure 8</label><caption><p>Kaplan-Meier curves of OS and CSS for patients in the low- and high-risk groups. (A) Kaplan-Meier curves of OS for patients in the low- and high-risk groups in the training cohort. (B) Kaplan-Meier curves of OS for patients in the low- and high-risk groups in the validation cohort. (C) Kaplan-Meier curves of CSS for patients in the low- and high-risk groups in the training cohort. (D) Kaplan-Meier curves of CSS for patients in the low- and high-risk groups in the validation cohort.</p></caption><graphic xlink:href="jcav16p1189g008" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinicopathological characteristics of patients with EOKC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th rowspan="1" colspan="1">Training cohort</th><th rowspan="1" colspan="1">Validation cohort</th><th rowspan="1" colspan="1">Temporal external validation</th><th rowspan="2" colspan="1"><italic>P</italic>-value</th></tr><tr><th rowspan="1" colspan="1">(N=8770)</th><th rowspan="1" colspan="1">(N=3759)</th><th rowspan="1" colspan="1">(N=1498)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">39.5 (6.15)</td><td rowspan="1" colspan="1">39.5 (6.03)</td><td rowspan="1" colspan="1">39.6 (5.76)</td><td rowspan="1" colspan="1">0.713/0.827</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.823/0.117</td></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">3355 (38.3%)</td><td rowspan="1" colspan="1">1446 (38.5%)</td><td rowspan="1" colspan="1">605 (40.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">5415 (61.7%)</td><td rowspan="1" colspan="1">2313 (61.5%)</td><td rowspan="1" colspan="1">893 (59.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.943/0.168</td></tr><tr><td rowspan="1" colspan="1">Black</td><td rowspan="1" colspan="1">1102 (12.6%)</td><td rowspan="1" colspan="1">467 (12.4%)</td><td rowspan="1" colspan="1">195 (13.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">other</td><td rowspan="1" colspan="1">696 (7.9%)</td><td rowspan="1" colspan="1">304 (8.1%)</td><td rowspan="1" colspan="1">139 (9.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">6972 (79.5%)</td><td rowspan="1" colspan="1">2988 (79.5%)</td><td rowspan="1" colspan="1">1164 (77.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Marital status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.764/0.433</td></tr><tr><td rowspan="1" colspan="1">Married</td><td rowspan="1" colspan="1">4972 (56.7%)</td><td rowspan="1" colspan="1">2142 (57.0%)</td><td rowspan="1" colspan="1">833 (55.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">other</td><td rowspan="1" colspan="1">3798 (43.3%)</td><td rowspan="1" colspan="1">1617 (43.0%)</td><td rowspan="1" colspan="1">665 (44.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Histologic subtypes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.830/0.004</td></tr><tr><td rowspan="1" colspan="1">Clear cell</td><td rowspan="1" colspan="1">5070 (57.8%)</td><td rowspan="1" colspan="1">2171 (57.8%)</td><td rowspan="1" colspan="1">890 (59.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">RCC</td><td rowspan="1" colspan="1">1709 (19.5%)</td><td rowspan="1" colspan="1">713 (19.0%)</td><td rowspan="1" colspan="1">292 (19.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Papillary</td><td rowspan="1" colspan="1">821 (9.4%)</td><td rowspan="1" colspan="1">346 (9.2%)</td><td rowspan="1" colspan="1">104 (6.9%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Chromophobe</td><td rowspan="1" colspan="1">694 (7.9%)</td><td rowspan="1" colspan="1">313 (8.3%)</td><td rowspan="1" colspan="1">144 (9.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">other</td><td rowspan="1" colspan="1">476 (5.4%)</td><td rowspan="1" colspan="1">216 (5.7%)</td><td rowspan="1" colspan="1">68 (4.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Grade</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.035/0.528</td></tr><tr><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">5146 (58.7%)</td><td rowspan="1" colspan="1">2210 (58.8%)</td><td rowspan="1" colspan="1">866 (57.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III/IV</td><td rowspan="1" colspan="1">2113 (24.1%)</td><td rowspan="1" colspan="1">963 (25.6%)</td><td rowspan="1" colspan="1">381 (25.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">1511 (17.2%)</td><td rowspan="1" colspan="1">586 (15.6%)</td><td rowspan="1" colspan="1">251 (16.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">T stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.881/0.443</td></tr><tr><td rowspan="1" colspan="1">T1/T2</td><td rowspan="1" colspan="1">7576 (86.4%)</td><td rowspan="1" colspan="1">3251 (86.5%)</td><td rowspan="1" colspan="1">1283 (85.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">T3/T4</td><td rowspan="1" colspan="1">1194 (13.6%)</td><td rowspan="1" colspan="1">508 (13.5%)</td><td rowspan="1" colspan="1">215 (14.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.453/0.943</td></tr><tr><td rowspan="1" colspan="1">N0</td><td rowspan="1" colspan="1">8370 (95.4%)</td><td rowspan="1" colspan="1">3577 (95.2%)</td><td rowspan="1" colspan="1">1431 (95.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N1</td><td rowspan="1" colspan="1">223 (2.5%)</td><td rowspan="1" colspan="1">93 (2.5%)</td><td rowspan="1" colspan="1">36 (2.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N2</td><td rowspan="1" colspan="1">177 (2.0%)</td><td rowspan="1" colspan="1">89 (2.4%)</td><td rowspan="1" colspan="1">31 (2.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">M stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.881/0.546</td></tr><tr><td rowspan="1" colspan="1">M0</td><td rowspan="1" colspan="1">8207 (93.6%)</td><td rowspan="1" colspan="1">3515 (93.5%)</td><td rowspan="1" colspan="1">1408 (94.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">M1</td><td rowspan="1" colspan="1">563 (6.4%)</td><td rowspan="1" colspan="1">244 (6.5%)</td><td rowspan="1" colspan="1">90 (6.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">AJCC Stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.810/0.625</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">6348 (72.4%)</td><td rowspan="1" colspan="1">2702 (71.9%)</td><td rowspan="1" colspan="1">1087 (72.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">962 (11.0%)</td><td rowspan="1" colspan="1">432 (11.5%)</td><td rowspan="1" colspan="1">159 (10.6%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">813 (9.3%)</td><td rowspan="1" colspan="1">341 (9.1%)</td><td rowspan="1" colspan="1">151 (10.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IV</td><td rowspan="1" colspan="1">647 (7.4%)</td><td rowspan="1" colspan="1">284 (7.6%)</td><td rowspan="1" colspan="1">101 (6.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Tumor size (cm)</td><td rowspan="1" colspan="1">5.05 (4.08)</td><td rowspan="1" colspan="1">5.03 (3.93)</td><td rowspan="1" colspan="1">4.91 (3.60)</td><td rowspan="1" colspan="1">0.761/0.147</td></tr><tr><td rowspan="1" colspan="1">Radiotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.327/0.117</td></tr><tr><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">8567 (97.7%)</td><td rowspan="1" colspan="1">3661 (97.4%)</td><td rowspan="1" colspan="1">1473 (98.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">203 (2.3%)</td><td rowspan="1" colspan="1">98 (2.6%)</td><td rowspan="1" colspan="1">25 (1.7%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Chemotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.175/0.8</td></tr><tr><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">8327 (94.9%)</td><td rowspan="1" colspan="1">3547 (94.4%)</td><td rowspan="1" colspan="1">1420 (94.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">443 (5.1%)</td><td rowspan="1" colspan="1">212 (5.6%)</td><td rowspan="1" colspan="1">78 (5.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Surgery</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.449/0.013</td></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">384 (4.4%)</td><td rowspan="1" colspan="1">151 (4.0%)</td><td rowspan="1" colspan="1">77 (5.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Local excision</td><td rowspan="1" colspan="1">189 (2.2%)</td><td rowspan="1" colspan="1">89 (2.4%)</td><td rowspan="1" colspan="1">46 (3.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Partial Nephrectomy</td><td rowspan="1" colspan="1">3370 (38.4%)</td><td rowspan="1" colspan="1">1407 (37.4%)</td><td rowspan="1" colspan="1">605 (40.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Radical Nephrectomy</td><td rowspan="1" colspan="1">4827 (55.0%)</td><td rowspan="1" colspan="1">2112 (56.2%)</td><td rowspan="1" colspan="1">770 (51.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Survival months</td><td rowspan="1" colspan="1">110(52.0)</td><td rowspan="1" colspan="1">111(53.1)</td><td rowspan="1" colspan="1">57.2 (18.9)</td><td rowspan="1" colspan="1">0.693/&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Overall survival</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.778/0.191</td></tr><tr><td rowspan="1" colspan="1">Dead</td><td rowspan="1" colspan="1">1659 (18.9%)</td><td rowspan="1" colspan="1">703 (18.7%)</td><td rowspan="1" colspan="1">262 (17.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alive</td><td rowspan="1" colspan="1">7111 (81.1%)</td><td rowspan="1" colspan="1">3056 (81.3%)</td><td rowspan="1" colspan="1">1236 (82.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Cancer-specific survival</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.838/0.228</td></tr><tr><td rowspan="1" colspan="1">Dead</td><td rowspan="1" colspan="1">1013 (11.6%)</td><td rowspan="1" colspan="1">439 (11.7%)</td><td rowspan="1" colspan="1">157 (10.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Alive</td><td rowspan="1" colspan="1">7757 (88.4%)</td><td rowspan="1" colspan="1">3320 (88.3%)</td><td rowspan="1" colspan="1">1341 (89.5%)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Univariable and multivariable Cox regression analysis of OS for EOKC patients in the training cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="3" rowspan="1">Univariate</th><th colspan="3" rowspan="1">Multivariable</th></tr><tr><th rowspan="1" colspan="1">HR</th><th rowspan="1" colspan="1">95%CI</th><th rowspan="1" colspan="1">
<italic>P</italic>
</th><th rowspan="1" colspan="1">HR</th><th rowspan="1" colspan="1">95%CI</th><th rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">1.025</td><td rowspan="1" colspan="1">1.016~1.034</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.022</td><td rowspan="1" colspan="1">1.014~1.031</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1.501</td><td rowspan="1" colspan="1">1.351~1.668</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.269</td><td rowspan="1" colspan="1">1.140~1.412</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Black</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">0.526</td><td rowspan="1" colspan="1">0.465~0.593</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.649</td><td rowspan="1" colspan="1">0.570~0.739</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">0.559</td><td rowspan="1" colspan="1">0.455~0.687</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.681</td><td rowspan="1" colspan="1">0.551~0.841</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Marital status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Married</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">1.527</td><td rowspan="1" colspan="1">1.387~1.682</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.405</td><td rowspan="1" colspan="1">1.272~1.553</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Histologic subtypes</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Clear cell</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Papillary</td><td rowspan="1" colspan="1">1.344</td><td rowspan="1" colspan="1">1.140~1.584</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.078</td><td rowspan="1" colspan="1">0.907~1.282</td><td rowspan="1" colspan="1">0.395</td></tr><tr><td rowspan="1" colspan="1">Chromophobe</td><td rowspan="1" colspan="1">0.328</td><td rowspan="1" colspan="1">0.237~0.455</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.339</td><td rowspan="1" colspan="1">0.243~0.472</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">RCC</td><td rowspan="1" colspan="1">1.781</td><td rowspan="1" colspan="1">1.587~2.000</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.181</td><td rowspan="1" colspan="1">1.042~1.338</td><td rowspan="1" colspan="1">0.009</td></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">3.572</td><td rowspan="1" colspan="1">3.063~4.166</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.715</td><td rowspan="1" colspan="1">1.455~2.021</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Grade</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III/IV</td><td rowspan="1" colspan="1">4.018</td><td rowspan="1" colspan="1">3.591~4.495</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.854</td><td rowspan="1" colspan="1">1.638~2.100</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">3.122</td><td rowspan="1" colspan="1">2.743~3.554</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.452</td><td rowspan="1" colspan="1">1.246~1.693</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">T stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">T1/T2</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">T3/T4</td><td rowspan="1" colspan="1">5.871</td><td rowspan="1" colspan="1">5.315~6.485</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.441</td><td rowspan="1" colspan="1">1.217~1.707</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">N stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N0</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N1</td><td rowspan="1" colspan="1">13.910</td><td rowspan="1" colspan="1">11.910~16.250</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.977</td><td rowspan="1" colspan="1">1.651~2.366</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">N2</td><td rowspan="1" colspan="1">18.620</td><td rowspan="1" colspan="1">15.710~22.070</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.721</td><td rowspan="1" colspan="1">1.388~2.133</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">M stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">M0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">M1</td><td rowspan="1" colspan="1">23.350</td><td rowspan="1" colspan="1">20.880~26.120</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">2.046</td><td rowspan="1" colspan="1">1.504~2.782</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">AJCC stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">1.677</td><td rowspan="1" colspan="1">1.411~1.993</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.325</td><td rowspan="1" colspan="1">1.097~1.602</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">4.058</td><td rowspan="1" colspan="1">3.527~4.668</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.899</td><td rowspan="1" colspan="1">1.535~2.349</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">IV</td><td rowspan="1" colspan="1">28.823</td><td rowspan="1" colspan="1">25.620~32.426</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">4.102</td><td rowspan="1" colspan="1">2.954~5.697</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Tumor size (cm)</td><td rowspan="1" colspan="1">1.055</td><td rowspan="1" colspan="1">1.051~1.059</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.009</td><td rowspan="1" colspan="1">1.000~1.018</td><td rowspan="1" colspan="1">0.043</td></tr><tr><td rowspan="1" colspan="1">Radiotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No/unknown</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">16.480</td><td rowspan="1" colspan="1">14.110~19.240</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.217</td><td rowspan="1" colspan="1">1.016~1.457</td><td rowspan="1" colspan="1">0.033</td></tr><tr><td rowspan="1" colspan="1">Chemotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No/unknown</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">14.090</td><td rowspan="1" colspan="1">12.510~15.870</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.114</td><td rowspan="1" colspan="1">0.942~1.318</td><td rowspan="1" colspan="1">0.209</td></tr><tr><td rowspan="1" colspan="1">Surgery</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Local excision</td><td rowspan="1" colspan="1">0.078</td><td rowspan="1" colspan="1">0.051~0.121</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.286</td><td rowspan="1" colspan="1">0.183~0.449</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Partial Nephrectomy</td><td rowspan="1" colspan="1">0.045</td><td rowspan="1" colspan="1">0.038~0.054</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.189</td><td rowspan="1" colspan="1">0.152~0.236</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Radical Nephrectomy</td><td rowspan="1" colspan="1">0.158</td><td rowspan="1" colspan="1">0.138~0.181</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.325</td><td rowspan="1" colspan="1">0.273~0.388</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Univariable and multivariable Cox regression analysis of CSS for EOKC patients in the training cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="3" rowspan="1">Univariate</th><th colspan="3" rowspan="1">Multivariable</th></tr><tr><th rowspan="1" colspan="1">HR</th><th rowspan="1" colspan="1">95%CI</th><th rowspan="1" colspan="1">
<italic>P</italic>
</th><th rowspan="1" colspan="1">HR</th><th rowspan="1" colspan="1">95%CI</th><th rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">1.010</td><td rowspan="1" colspan="1">1.000~1.020</td><td rowspan="1" colspan="1">0.032</td><td rowspan="1" colspan="1">1.009</td><td rowspan="1" colspan="1">0.999~1.018</td><td rowspan="1" colspan="1">0.082</td></tr><tr><td rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">1.590</td><td rowspan="1" colspan="1">1.390~1.820</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.316</td><td rowspan="1" colspan="1">1.144~1.512</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Race</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Black</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">White</td><td rowspan="1" colspan="1">0.545</td><td rowspan="1" colspan="1">0.466~0.638</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.690</td><td rowspan="1" colspan="1">0.583~0.816</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">0.637</td><td rowspan="1" colspan="1">0.493~0.822</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.755</td><td rowspan="1" colspan="1">0.580~0.983</td><td rowspan="1" colspan="1">0.037</td></tr><tr><td rowspan="1" colspan="1">Marital status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Married</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">1.290</td><td rowspan="1" colspan="1">1.140~1.460</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.099</td><td rowspan="1" colspan="1">0.965~1.251</td><td rowspan="1" colspan="1">0.156</td></tr><tr><td rowspan="1" colspan="1">Histologic subtype</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Clear cell</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Papillary</td><td rowspan="1" colspan="1">1.189</td><td rowspan="1" colspan="1">0.943~1.500</td><td rowspan="1" colspan="1">0.140</td><td rowspan="1" colspan="1">0.994</td><td rowspan="1" colspan="1">0.779~1.269</td><td rowspan="1" colspan="1">0.964</td></tr><tr><td rowspan="1" colspan="1">Chromophobe</td><td rowspan="1" colspan="1">0.284</td><td rowspan="1" colspan="1">0.177~0.455</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.279</td><td rowspan="1" colspan="1">0.173~0.450</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">RCC</td><td rowspan="1" colspan="1">2.109</td><td rowspan="1" colspan="1">1.820~2.444</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.296</td><td rowspan="1" colspan="1">1.104~1.521</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Other</td><td rowspan="1" colspan="1">5.354</td><td rowspan="1" colspan="1">4.491~6.382</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.937</td><td rowspan="1" colspan="1">1.600~2.346</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Grade</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">I/II</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III/IV</td><td rowspan="1" colspan="1">8.250</td><td rowspan="1" colspan="1">7.010~9.710</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">2.367</td><td rowspan="1" colspan="1">1.982~2.827</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">5.170</td><td rowspan="1" colspan="1">4.290~6.230</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.565</td><td rowspan="1" colspan="1">1.256~1.949</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">T stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">T1/T2</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">T3/T4</td><td rowspan="1" colspan="1">10.600</td><td rowspan="1" colspan="1">9.330~12.000</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.285</td><td rowspan="1" colspan="1">1.075~1.534</td><td rowspan="1" colspan="1">0.006</td></tr><tr><td rowspan="1" colspan="1">N stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N0</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">N1</td><td rowspan="1" colspan="1">22.400</td><td rowspan="1" colspan="1">18.900~26.500</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.956</td><td rowspan="1" colspan="1">1.618~2.363</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">N2</td><td rowspan="1" colspan="1">29.000</td><td rowspan="1" colspan="1">24.100~34.800</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.648</td><td rowspan="1" colspan="1">1.316~2.064</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">M stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">M0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">M1</td><td rowspan="1" colspan="1">40.400</td><td rowspan="1" colspan="1">35.400~46.100</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.948</td><td rowspan="1" colspan="1">1.408~2.694</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">AJCC stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">4.610</td><td rowspan="1" colspan="1">3.610~5.900</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">3.044</td><td rowspan="1" colspan="1">2.339~3.961</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">12.820</td><td rowspan="1" colspan="1">10.450~15.700</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">5.377</td><td rowspan="1" colspan="1">4.112~7.030</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">IV</td><td rowspan="1" colspan="1">98.880</td><td rowspan="1" colspan="1">82.340~118.800</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">12.197</td><td rowspan="1" colspan="1">8.377~17.759</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Tumor size (cm)</td><td rowspan="1" colspan="1">1.060</td><td rowspan="1" colspan="1">1.060~1.070</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.014</td><td rowspan="1" colspan="1">1.005~1.023</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Radiotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No/unknown</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">23.200</td><td rowspan="1" colspan="1">19.600~27.300</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.263</td><td rowspan="1" colspan="1">1.048~1.521</td><td rowspan="1" colspan="1">0.014</td></tr><tr><td rowspan="1" colspan="1">Chemotherapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No/unknown</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">22.900</td><td rowspan="1" colspan="1">20.000~26.200</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">1.137</td><td rowspan="1" colspan="1">0.953~1.357</td><td rowspan="1" colspan="1">0.154</td></tr><tr><td rowspan="1" colspan="1">Surgery</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Reference</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Local excision</td><td rowspan="1" colspan="1">0.015</td><td rowspan="1" colspan="1">0.005~0.047</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.123</td><td rowspan="1" colspan="1">0.039~0.388</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Partial Nephrectomy</td><td rowspan="1" colspan="1">0.015</td><td rowspan="1" colspan="1">0.011~0.020</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.130</td><td rowspan="1" colspan="1">0.092~0.185</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Radical Nephrectomy</td><td rowspan="1" colspan="1">0.150</td><td rowspan="1" colspan="1">0.128~0.175</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.342</td><td rowspan="1" colspan="1">0.278~0.421</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></table-wrap></floats-group></article>